A room offer does not answer whether an aged care home can continue a resident’s medicinal cannabis. Families need to verify the exact product, prescriber, legal access pathway, pharmacy, storage, administration times, monitoring and cost before agreeing to move. A verbal assurance that the home “manages medications” is not enough for a product that may be unapproved, privately priced and subject to state or territory controls.
The Therapeutic Goods Administration says most medicinal cannabis products supplied in Australia are unapproved medicines. They are generally accessed through the Special Access Scheme or an Authorised Prescriber pathway. The TGA also states that unapproved medicinal cannabis is not covered by the Pharmaceutical Benefits Scheme and that private suppliers set prices. Residential aged care providers, meanwhile, must ensure medicines are prescribed for the individual, administered safely and monitored and reviewed by registered health practitioners. Those rules create a practical pre-admission test: can this particular home operate the existing treatment without an interruption or an unexplained new bill?
Identify the exact medicine and access pathway
Prepare a current medication list showing the product name, formulation, strength, dose, route, schedule, indication, prescriber and dispensing pharmacy. Record whether it is entered in the Australian Register of Therapeutic Goods or supplied as an unapproved product. If unapproved, identify whether access is through SAS or an Authorised Prescriber.
Do not describe the medicine only as “CBD oil” or “cannabis”. Different products and cannabinoid concentrations are not interchangeable. The home needs the exact prescription and access information to check whether its pharmacy and medication system can obtain and administer the same item.
Confirm who will prescribe after admission
Ask whether the current prescriber will continue after the move and whether that clinician can work with the home’s medication chart and review process. If not, obtain the name of the practitioner expected to take responsibility and arrange a clinical handover before the first prescription expires.
The TGA access pathway belongs to the prescribing process; it does not transfer responsibility to the aged care home. A home should not promise that a new doctor will automatically repeat an unapproved medicine. Request a written continuity plan that separates the existing authority, future prescribing and any review the new practitioner requires.
Test pharmacy supply and lead times
Residential aged care homes commonly use an electronic National Residential Medication Chart to coordinate prescribing, supply and administration of PBS and non-PBS medicines. Ask whether the home’s contracted pharmacy can supply the exact medicinal cannabis product and record it correctly in the medication chart. If an external pharmacy is needed, clarify delivery, after-hours access and who receives the parcel.
Confirm normal order time, refill timing and the contingency for stock delays. Some products cannot be substituted without a new clinical decision. Keep enough lawful supply for the agreed transition period, but do not arrive with an undeclared product that the home cannot store or administer.
Separate medicine cost from aged care fees
The TGA states that unapproved medicinal cannabis is not PBS funded and prices are set by private suppliers. Ask for the current product price, dispensing and delivery charges, consultation fees and frequency of review. Then ask the home whether it adds any separately agreed pharmacy, courier or medication service charge.
Compare a full month rather than one bottle. Include wastage when packaging or dose changes, the cost of urgent replacement and travel or telehealth fees for the prescriber. Keep accommodation payments, aged care contributions, optional living services and private medication expenses on separate lines so a low room price does not hide a high recurring treatment cost.
Check administration at every required time
Ask who administers each dose, how the product is measured, where it is stored and what happens on evening, night and weekend shifts. Confirm whether the home permits self-administration after assessment and how capacity, safety and secure storage are documented. A dose required at a precise time needs a staffing answer, not a general medication round schedule.
The strengthened Aged Care Quality Standards require safe and appropriate prescribing, administration, monitoring and review. Ask the home to explain how this obligation is applied to the proposed resident, including missed doses, refusal, swallowing difficulty and changes in alertness.
Plan monitoring and adverse-event escalation
Record the intended benefit and the signs that require review. Depending on the product and resident, relevant concerns may include sedation, confusion, dizziness, falls, appetite change or interaction with other medicines. The family should not direct treatment, but it should understand who observes, documents and contacts the prescriber.
Ask for the escalation route when the resident becomes unusually drowsy, falls or is transferred to hospital. Confirm how the medicinal cannabis appears on transfer documents so it is not omitted or restarted without reconciliation. The home should also explain how it reports and learns from medicine-related adverse events.
Distinguish treatment from restrictive practice
Medicinal cannabis prescribed for a clinical condition is not automatically a restrictive practice. However, any medicine used primarily to influence behaviour rather than treat a diagnosed condition raises separate consent and restrictive-practice questions. The Aged Care Quality and Safety Commission emphasises informed consent for medication and the last-resort nature of restrictive practices.
Ask the prescriber and home to document the purpose, consent, review interval and alternatives. This protects the resident from both inappropriate continuation and abrupt cessation. A family should reject any suggestion that a sedating effect is itself the care plan.
Model an interrupted-supply scenario
Before entry, ask the home to walk through a realistic delay: the pharmacy cannot source the product, the authorisation needs renewal, or the prescriber is unavailable. Who contacts whom? Is there an approved alternative plan? Who pays for an urgent consultation or delivery? What symptoms trigger clinical review rather than simply waiting?
Do not ask the home to guarantee continuous commercial supply. Ask for documented responsibilities and lead times. The strongest offer is one that recognises the limits, starts renewal early and avoids leaving the family to improvise after the last dose.
Read the agreement and care plan together
The residential service agreement and accommodation agreement govern different parts of the move. The medication and clinical plan should state the practical treatment arrangements, while the fee documents should identify private charges and consent processes. Check that no broad clause allows unspecified medication expenses without notice.
Clarify what happens if the home’s clinical assessment concludes that it cannot safely provide the treatment. Do not surrender another placement or pay an irreversible amount until the acceptance of the actual medication plan is recorded. If a representative signs, make sure the signature does not create an unintended personal guarantee for open-ended private costs.
Compare homes using the same evidence
For each room, score the named prescriber, legal access pathway, supplying pharmacy, order lead time, chart compatibility, dose coverage, secure storage, self-administration policy, monitoring, hospital transfer process and monthly private cost. Mark answers as confirmed, conditional or missing.
A home that already handles medicinal cannabis may offer a smoother transition, but experience must still be verified for the exact product and resident. A home without prior experience is not automatically unsuitable if it has obtained clinical and pharmacy confirmation and presents a safe, costed plan.
Ask intermediaries about commissions
If a placement adviser or directory recommends a home, ask whether the provider pays a referral or admission commission. Request the scope of the search and whether homes without commercial agreements were considered. A disclosed commission does not decide suitability, but it helps the family judge the recommendation.
Confirm current vacancy, clinical acceptance, medicine supply and fees directly with the home, prescriber and pharmacy. An intermediary cannot authorise an unapproved medicine or guarantee admission.
How Curalune can help with the decision
Curalune can select options using location, care needs, medicinal cannabis formulation, dosing schedule, pharmacy pathway and budget. Through its fuller contact service, Curalune can ask shortlisted homes about current availability, clinical review, prescriber continuity, supply, private charges and next steps, then organise the responses for comparison.
Curalune does not guarantee availability, reservation, medicine supply, clinical approval or admission. Those decisions remain with providers, health practitioners, pharmacies, regulators and the resident or authorised decision-maker.
Frequently asked questions
Is medicinal cannabis automatically covered by the PBS?
No. The TGA states that unapproved medicinal cannabis is not covered by the PBS and private suppliers set prices. Confirm the status and total monthly cost of the exact product.
Can the aged care home use the resident’s existing prescription?
Possibly, but it must verify the prescription, access pathway, charting, pharmacy supply and administration arrangements. Do not assume the existing community process will continue unchanged.
Can a home refuse admission because of medicinal cannabis?
A provider must assess whether it can safely meet the individual’s needs. Ask for a case-specific clinical decision and reasons, then compare homes with an evidenced continuity plan.
Can Curalune guarantee a home will continue the treatment?
No. Curalune can structure selection and contact, but cannot guarantee a place, prescribing decision, pharmacy supply, price or admission.